TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immuron Limited ( (AU:IMC) ) has issued an update.
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the AusBiotech Invest 2025 conference, highlighting the company’s advancements in biopharmaceuticals. This presentation underscores Immuron’s commitment to leveraging its proprietary technology to address infectious diseases, potentially enhancing its market position and offering significant implications for stakeholders, particularly in the areas of travelers’ health and gastrointestinal treatments.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for treating infectious diseases. The company’s primary product, Travelan®, is designed to reduce the risk of travelers’ diarrhea, and it is marketed as a therapeutic good in Australia, a natural health product in Canada, and a dietary supplement in the U.S. Immuron also develops other products like IMM-529 for Clostridioides difficile infection and ProIBS® for IBS symptoms.
Average Trading Volume: 203,461
Technical Sentiment Signal: Hold
Current Market Cap: A$21.46M
Find detailed analytics on IMC stock on TipRanks’ Stock Analysis page.